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Background: Open repair (OR) of abdominal aortic aneurysms (AAAs) is a major surgical procedure with elevated
morbidity and a low but definite mortality. Advocates of endovascular repair (EVAR) claim decreased complication rates
and outcome equal to OR.
Methods: Data of all patients with infrarenal AAA that was treated electively, both with OR and EVAR, at Mayo Clinic
Rochester between December 1, 1999 and December 1, 2001 were retrospectively reviewed. Thirty-day morbidity and
mortality and early clinical outcomes were assessed and compared.
Results: Three hundred fifty-five patients underwent treatment: 261 patients, including 229 males and 32 females (mean
age: 73 years; range: 52 to 90 years) underwent OR, and 94 patients including 85 males and 9 females (mean age: 77
years; range: 61 to 98 years) underwent EVAR (AneuRx: 53, Ancure: 38, Endologix: 3). Median AAA size was 57 mm
in both groups. There were more high-risk patients in the EVAR group (27% vs 14%, P  .007). Thirty-day mortality
rates were 1.1 % (3/261) for OR and 0 for EVAR (P  NS). Cardiac and pulmonary complications were less frequent
after EVAR (11% vs 22%, P  .02, and 3% vs 16%, P  .001, respectively), but graft-related complications were more
frequent (13% vs 4%, P  .002). The association between type of repair and cardiac, pulmonary, and graft complications
remained statistically significant after adjusting for age, gender, and high-risk status. The multivariate odds ratios (EVAR
vs OR) for cardiac, pulmonary, and graft complications were 0.35 (95% confidence interval [CI]: 0.17 to 0.74), 0.14 (95%
CI: 0.04 to 0.47), and 3.81 (95% CI: 1.51 to 9.58), respectively. Primary and secondary patency and freedom-from-
reintervention rates at 1 year were lower after EVAR (83% vs 98%, P < .001; 96% vs 99%, P .02; 65% vs 93%, P < .001,
respectively).
Conclusions: Both elective OR and EVAR can be performed with low mortality, but cardiac and pulmonary complications
are less frequent and less severe after EVAR. The tradeoff of EVAR is a higher rate of graft-related complications, with
more reinterventions and a lower graft patency rate at 1 year. These results should be considered before EVAR is offered
to patients with AAA. (J Vasc Surg 2004;39:497-505.)
Open repair (OR) of abdominal aortic aneurysms
(AAAs) is a major surgical procedure that is associated with
elevated morbidity, with several weeks’ convalescence, and
with a low but definite mortality. Phase II nonrandomized
multicenter clinical trials1,2 suggested that endovascular
AAA repair (EVAR) was associated with decreased compli-
cation rates, less blood transfusion, reduced ICU and hos-
pital stay, and improved early outcome compared with
conventional OR. In the AneuRx trial, perioperative major
morbidity was significantly reduced, from 23% in the sur-
gery group to 12% in the stent graft group; and only 12% of
the patients in the stent graft group received a blood
transfusion, compared with 40% in the surgery group. In
the Ancure trial, significant reduction in perioperative car-
diac, respiratory, and bleeding complications were noted in
the stent graft group compared with the surgery group.
Our initial experience with EVAR has been favorable,
and early results of the first hundred patients treated by
endovascular repair have been reported.3
The aim of this study was to compare the early results of
elective EVAR with open repair that was performed during
the same period at the Mayo Clinic in Rochester, Minne-
sota.
METHODS
We retrospectively reviewed the clinical and radiologic
data for all patients with infrarenal degenerative AAA that
was treated electively between December 1, 1999 and
December 1, 2001. The decision of whether to treat a
patient through an open or an endovascular approach was
left to the surgeon’s and the patient’s preference and was
not based on a protocol, except for in the cases of nine
patients who were enrolled in the Endologix trial (open
repair: 6, endovascular repair: 3). In general, endovascular
repair was recommended for patients who were at higher
risk of complications from open surgical repair, either be-
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cause of associated comorbidities or because of relative
contraindication to open repair, such as a hostile abdomen.
Computed tomography (CT) scan with intravenous con-
trast, using 2.5- or 3-mm cuts, was performed for all
patients who underwent EVAR. Contrast aortography or,
less frequently, magnetic resonance aortography, were per-
formed selectively to define the aortoiliac morphology. Full
evaluation for EVAR was not performed for all patients
who underwent open repair. Patients with juxtarenal AAA,
associated planned visceral or renal revascularization, my-
cotic or false aneurysms, associated aortic dissection, or
ruptured aneurysms were excluded. Demographic data,
comorbidities, aortic morphology data, fitness for surgery,
potential contraindications to open surgery, intraoperative
data, morbidity, and mortality were recorded using the
standards of the Joint Vascular Societies. Patients at higher
risk of complications were defined as patients with one or
more of the following factors: home oxygen dependency,
severe chronic obstructive or restrictive pulmonary disease
(FEV1 of 1.0), serum creatinine of 1.8 mg/dL, myo-
cardial infarction in the last 6 months before treatment,
severe class IV angina or severe valvular heart disease, left
ventricular ejection fraction of 30%, and Child B or C
cirrhosis. Relative contraindications to open repair in-
cluded body mass index of 35, presence of an ostomy,
hostile abdomen, recent or severe pancreatitis or peritoni-
tis, prior abdominal or pelvic radiotherapy, active meta-
static cancer, dementia, or severe neurologic impairment.
Any death or complications occurring during the first
30-day postoperative period were included in the mortality
and morbidity rates. Morbidities were defined based on the
standards of the Joint Vascular Societies (Table I, online
only).4-6 A severity scale was also recorded for each com-
plication when appropriate. The following were recorded:
lengths of intensive care unit (ICU) stay, intermediate care
area stay, hospital stay, and postoperative stay. Number of
days before resuming diet was also recorded.
Primary patency, primary assisted patency, and second-
ary patency were defined as suggested in the standards for
reports dealing with lower extremity ischemia.4 Angio-
plasty and stenting used in the graft or its landing zone to
treat endoleak during follow-up was considered to disqual-
ify the graft from primary patency because these interven-
tions could modify the natural history of the graft, either
increasing or decreasing its patency. Readmission and rein-
tervention related to the AAA treatment during the first
year were also recorded. Reinterventions were defined as
any therapeutic procedures done after the initial AAA treat-
ment for a complication related to the AAA. Diagnostic
angiography for endoleak or endoscopy for colonic isch-
emia suspicion were not considered reintervention. Success
rate, defined as freedom from AAA-related death, AAA
rupture, and conversion, was estimated for both group and
constituted a secondary endpoint. A conversion was de-
fined as an open procedure to repair the aneurysm or to
treat a complication of the aneurysm repair such as a false
aneurysm. All patients undergoing EVAR were followed
according to a predetermined protocol that included a CT
scan and duplex ultrasonography at 1, 3, 6, 12, 18, and 24
months and every 6 months thereafter. All radiologic exams
done after endovascular repair were reviewed for migration,
endoleak, and graft limb occlusions, and the maximal trans-
verse and anteroposterior aneurysm diameters were re-
corded.
A minimum of 30 days of follow-up was obtained for all
patients for the 30-day morbidity and mortality complica-
tions. Patients who were not evaluated in the year before
March 2002 were considered lost to follow-up. For the
survival analysis, 41 patients (16%) in the OR group and 3
patients (3%) in the EVAR group were lost to follow-up.
The Kaplan-Meier method was used to provide estimates
and confidence intervals for event rates. Because this
method censors patients at the time that they were lost to
follow-up, the confidence intervals provided do take into
account their status as lost to follow-up.
Statistical analysis. All data were recorded using Ex-
cel software and then transferred to SAS software for statis-
tical analysis. Descriptive statistics, including means, medi-
ans, standard deviations, ranges, and proportions, were
calculated as appropriate. Chi-square or Fisher’s exact tests,
as appropriate, were used to compare nominal variables
between the two groups. American Association of Anesthe-
siologists class was assessed for association with surgical
procedure using an exact test for the ordered contingency
table. Wilcoxon rank-sum tests were used for tests of asso-
ciation with continuous variables, such as age, operative
time, anesthesia time, and hospital length of stay.
Logistic regression models were used to analyze the
association between type of surgical procedure and the
30-day outcomes of cardiac, pulmonary, and graft compli-
cations. Multiple variable logistic regression models were
used to adjust for age and high-risk status (these were
significant univariately) as well as gender. The univariate
and multivariate odds ratios (EVAR vs OR) with 95%
confidence intervals are reported for the surgical repair
group variable. For 30-day deaths, there were too few
events (3 in OR group; 0 in EVAR group) for a multiple-
variable analysis.
Primary patency, primary assisted patency, secondary
patency, reintervention, and freedom from a combined
failure endpoint incorporating AAA-related death, AAA
rupture, or conversion were estimated with the Kaplan-
Meier survival method. Significance tests comparing the
two groups were performed with log-rank tests. Multiple-
variable Cox proportional hazards models were used to
adjust for possible confounding variables (age, gender, and
high-risk status) in the analysis of the primary patency and
reintervention endpoints. As with the 30-day death out-
come, there were too few events to perform multiple vari-
able analysis, adjusting for age, gender, and high-risk status
for the endpoints of primary assisted patency, secondary
patency, and freedom from AAA-related death, AAA rup-
ture, or conversion. The univariate and multivariate hazard
ratios (EVAR vs OR) and the associated 95% confidence
intervals were reported for the type of surgical repair vari-
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able. A P value of .05 was considered statistically signifi-
cant for all analyses.
RESULTS
Demographic data
The records of 362 patients with an infrarenal AAA
treated electively between December 1, 1999 and Decem-
ber 1, 2001 were reviewed. Seven of these patients did not
consent to research, leaving 355 patients, who constituted
the study group. Two hundred sixty-one patients, 229 men
and 32 women (mean age: 73 years, range: 52 to 90 years)
underwent an OR, and 94 patients, 85 men and 9 women
(mean age: 77 years, range: 61 to 98) underwent an EVAR.
Preoperative data
All patients were asymptomatic from their AAA and
were admitted for elective treatment. Pertinent surgical risk
factors and comorbidities are reported in Table II (online
only). There was no statistically significant difference be-
tween both group ASA classes. However, there were more
high-risk patients in the EVAR group than in the OR group
(26.6% (25/94) vs 14.2% (37/261), P  .007). The
frequencies of the different factors defining high-risk cate-
gorization are reported in Table III. Contraindications to
open repair were more frequent in the EVAR group than in
the OR group (21.3% (20/94) vs 8.0% (21/261), P 
.0006, Table IV).
Preoperative CT and angiography were done more
often in the EVAR group (100% vs 71% and 77% vs 25%,
respectively, P  .0001 for both). Thirteen patients
(13.8%) in the EVAR group underwent preoperative inter-
nal iliac artery embolization.
Median maximal aneurysm size was 57 mm for both
groups. Data related to aneurysm morphology and indica-
tion for treatment are reported in Table V (online only).
For the 94 EVAR patients, mean aortic neck length was
23.1 10.3 mm (median 20 mm, range 6 to 62 mm),
mean neck diameter was 24.7 1.8 mm (median  25.5
mm, range 19 to 27). Neck angulation was60° in 79 of
94 patients (84%) and 60° in 15 (16%).
Intraoperative data
All cases were performed under general anesthesia.
Median operative and anesthesia times, and estimated
blood loss were all higher in the OR group (Table VI,
online only).
OR group. Primary procedure consisted of endoaneu-
rysmorrhaphy with aorto-aortic interposition graft done in
Table III. High-risk patients
Variable P value OR* EVAR*
Total high-risk Status .007 14.2 (37/261) 26.6 (25/94)
O2 dependence .22 1.5 (4/261) 4.3 (4/94)
Severe COPD .03 3.8 (10/261) 9.6 (9/94)
Recent MI (6 m) 1.0 1.1 (3/261) 1.1 (1/93)
Angina class IV or severe
valvular heart disease
.02 0.8 (2/261) 5.3 (5/94)
EF 30% .11 3.0 (6/201) 7.4 (6/81)
Cirrhosis .07 0 (0/261) 2.1 (2/94)
Serum creatinine 1.8 mg/dL .007 6.9 (18/261) 3.2 (3/94)
COPD, Chronic obstructive pulmonary disease; MI, myocardial infarction; CAD, coronary artery disease; EF, ejection fraction.
*All OR and EVAR values are % (n).
Table IV. Relative contraindications to open repair
Variable P value OR* EVAR*
Total relative contraindication 0.0006 8.0 (21/261) 21.3 (20/94)
Total relative contraindication
including BMI 35
0.01 15.9 (41/258) 27.7 (26/94)
Ostomy 0.01 1.5 (4/261) 7.5 (7/94)
Prior abdominal/pelvic
radiation
0.70 2.3 (6/261) 3.2 (3/94)
Hostile abdomen 0.12 0.8 (2/261) 3.2 (3/94)
BMI
Mean  SD 0.85 27.9  4.6 28.0  4.6
35, (%) 0.91 8 9
Severe pancreatitis, peritonitis 0.04 0.8 (2/261) 4.3 (4/94)
Dementia 0.06 0.4 (1/261) 3.2 (3/94)
Life expectancy  2 y 0.02 0 3.2 (3/94)
Active cancer 0.02 2.7 (7/261) 9.6 (9/94)
BMI, Body mass index.
*All OR and EVAR values are % (n) unless otherwise noted.
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 3 Elkouri et al 499
37.5% of patients (98/261) and different aortoiliofemoral
reconstructions in 62.5% of patients (aorto-common iliac in
37.5% of patients [98/261], aortobifemoral in 5.4% of
patients [14/261], aorto-external iliac in 3.8% of patients
[10/261], and other combination in 41 patients). The
transperitoneal approach was the most frequently used
approach (93.1%, 243 of 261 patients). Groin incisions
were done in 6.9% of patients (18/261). Associated sec-
ondary procedures were done in 21.8 % of patients (57/
261) and included the following: inferior mesenteric artery
or accessory renal artery reimplantation (15), internal iliac
artery bypass (5), incision hernia or umbilical hernia repair
(13), femoral aneurysm repair (4), femoral artery endarter-
ectomy or profundoplasty (5), cholecystectomy (2), and
other (13). Intraoperative complications occurred in two
patients and consisted of one enterotomy and one ureter
transection. Both were recognized and treated
intraoperatively.
EVAR group. The devices used to complete EVAR
were Ancure (Guidant, Menlo Park, CA) in 40.4% (38/94),
AneuRx (Medtronic, Sunnyvale, CA) in 56.4% (53/94), and
Endologix (Irvine, CA) in 3.2% (3/94). EVAR was per-
formed through groin incision in 91.5% (86/94) of patients.
Seven patients (7.4%) needed an additional flank incision for
retroperitoneal exposure of the iliac arteries. There was one
(1.1%) immediate conversion to open repair in the
EVAR group because of small iliac size that would not
allow insertion of the device. Secondary procedures were
done in 7.4% (7/94) of patients and included femoral
artery repair (4), internal iliac artery bypass (2), and
embolectomy (1). Eighteen patients needed iliac angio-
plasty before the device insertion. Additional stenting
was used over the proximal and distal attachment site in
9.6% (9/94) and 42.6% (40/94) of EVAR patients,
respectively. Completion angiogram revealed 55 en-
doleaks in 46 patients: 25 type I endoleak, 5 type III
endoleak, and 25 type II endoleak. Successful treatment
of types I and III endoleaks was achieved in all patients
with repeat balloon angioplasty and/or additional stent
placement before completion of the EVAR procedure.
Table VIII. Thirty-day complications rates with severity code
Variable* P value OR EVAR
Cardiac morbidity,† n (%) .02 21.8 (57/261) 10.6 (10/94)
Arrhythmia .11 12.3 (32/261) 6.4 (6/94)
Congestive heart failure 1.0 3.5 (9/261) 3.2 (3/94)
Myocardial infarction .25 5.4 (14/261) 2.1 (2/94)
Hypertension .77 4.6 (12/261) 3.2 (3/94)
Pulmonary morbidity,‡ n (%) .001 16.1 (42/261) 3.2 (3/94)
Pneumonia .02 11.5 (30/261) 3.2 (3/94)
Respiratory insufficiency .02 7.7 (20/261) 1.1 (1/94)
Pulmonary embolism .58 1.5 (4/261) 0
Renal morbidity, n (%) 1.0 4.2 (11/261) 4.3 (4/94)
Wounds morbidity§ .82 5.7 (15/261) 6.4 (6/94)
Graft-related complications .002 3.8 (10/261) 12.8 (12/94)
Loss of patency .02 0.8 (2/261) 5.3 (5/94)
*Severity code according to SVS.
†OR: 67 complications in 57 patients, EVAR: 14 complications in 10 patients.
‡OR: 54 complications in 42 patients, EVAR: 4 complications in 3 patients.
§OR: 17 complications in 15 patients, EVAR: 6 complications in 6 patients.
OR: 11 complications in 10 patients, EVAR: 14 complications in 12 patients.
Table VII. Thirty-day postoperative data
Variable P value OR EVAR
ICU median stay, d (range) .0001 2 (1,90) n  258 1 (0, 15)
ICA median stay, d (range) .0001 1 (0, 28) 0 (0, 35)
Median length of stay, d (range) .0001 8 (3, 128) 3 (1, 42)
Median length of postoperative stay, d
(range)
.0001 7 (2, 128) 3 (1, 35)
Median time for bowel function
resolution, d (range)
.0001 4 (2, 17) n  256 1 (1, 13) n  92
Transfusion, % (n) .0001 51.3 (134/261) 26.6 (25/94)
Thirty-day mortality rate, % (n) .57 1.2 (3/261) 0 (0/94)
Thirty-day reintervention rate,* % (n) .06 4.3 (11/253) 9.6 (9/94)
Thirty-day rehospitalization rate,† % (n) .59 8.8 (22/249) 10.8 (10/93)
*Excluding those who died within the first 30 days (3 in OR; 0 in OR) and those without 30 days of follow-up.
†Excluding those who died within the first 30 days (3 in OR; 0 in ER), those without 30 days of follow-up, and those not discharged at 30 days.
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Postoperative data
Thirty-day mortality. There was no statistically sig-
nificant difference in the 30-day mortality rates between
groups. There were no 30-day deaths in the EVAR group.
Three patients died after OR, two from ventricular fibrilla-
tion occurring on the third and ninth postoperative days
and one after hemorrhagic shock due to bleeding from the
proximal aortic anastomosis on the second postoperative
day, for a 30-day mortality rate of 1.1% (3/261).
Hospital length of stay. Median hospital, postopera-
tive, ICU, and intermediate care area length of stay were all
significantly shorter in the EVAR group (Table VII). Me-
dian postoperative stay in the EVAR group was 3 days,
compared with 7 days in the OR group. Median time to
resume bowel function was also shorter in the EVAR group
(1 vs 4 days, P  .0001).
Thirty-day morbidity. Cardiac complications were
significantly less frequent in the EVAR group (11%) com-
pared with the OR group (22%; Table VIII). This differ-
ence remained statistically significant when only MI, CHF,
or arrhythmia were compared (9% vs 18%, P  .02). We
also compared the rates of the individual complications
defining the cardiac complication group. These rates were
all higher in the OR group compared with the EVAR
group, without reaching statistical significance.
The pulmonary complication rate was lower in the
EVAR group (3% vs 16%, P  .001). There was no differ-
ence in renal or wounds-related complications between the
two groups. The graft-related complication rate was signif-
icantly higher in the EVAR group compared with in the OR
group (13% vs 4%). Proportion of patients with lower limb
ischemia or stenosis requiring treatment within the 30-day
postoperative period was higher in the EVAR group com-
pared with in the OR group (5.3% vs 0.8%, P  .02).
The associations between the surgical repair type
(EVAR vs OR) and the 30-day rates of cardiac, pulmonary,
and graft-related complications remained significant after
adjusting for age, gender, and high status in multiple
logistic regression models (Table IX). A more detailed
listing of complication subtypes is provided in Table X
(online only)
The proportion of patients receiving blood products
during the first 30-day postoperative period was signifi-
cantly higher after OR compared with after EVAR (51.3%
vs 26.6%, P .0001). In those who received red blood cell
transfusion, the median amount of blood received was 2 U
in both groups (ranges, OR: 1 to 47 U, vs EVAR: 1 to 13
U).
Readmission rate within the first 30 days was not sig-
nificantly higher in the EVAR group (EVAR vs OR: 10.8%
vs 8.8%, P .59). The median number of hospitalized days
within the first 30 days was higher after OR (7 vs 3 days, P
 .0001). The 30-day reintervention rate was higher in the
EVAR group compared with the OR group (9.6% vs 4.3%,
P  .06).
Survival curve
Freedom-from-reintervention rates were significantly
different between both groups (P .001; Fig 1). The rates
at 1 year for the EVAR and OR group were 65% (95% CI:
51% to 84%) and 93% (95% CI: 89% to 96%), respectively.
Twenty-one patients in the OR group required 22 reinter-
ventions during the first year: 12 were related to wounds
complications (infection [2], dehiscence [8] or lymphocele
[2]), 8 were related to vascular complications (hemorrhage
or hematoma [3], thrombosis [3], emboli [1], or other
[1]), and 2 were for other reasons. Only one of these
reinterventions was done with an endovascular approach.
Twenty patients in the EVAR group underwent reinterven-
tions during the first year: 2 were related to wounds com-
plications (infection [1], lymphocele [1]), 8 were related to
endoleak treatment (type 1 [3], type II [5]), and 10 were
related to vascular complications (open repair after AAA
rupture [1], limb occlusion or severe stenosis requiring
treatment [7], and renal artery stenting [2]). Most of these
reinterventions were done through an endovascular ap-
proach (75% [15/20]).
Twenty-six patients (27.7%) had an endoleak detected
on CT during follow-up. Maximal aneurysm diameter re-
mained the same in 63 patients and decreased in 28 pa-
tients. Two patients had an increase in their maximal aneu-
rysm size during follow-up. The first case required







with 95% CI †
Multivariate ratios for
treatment variable
with 95% CI †
Logistic regression
Complications
Cardiac .02 .006 0.43 (0.21, 0.87) 0.35 (0.17, 0.74)
Pulmonary .004 .002 0.17 (0.05, 0.57) 0.14 (0.04, 0.47)
Graft .004 .005 3.67 (1.53, 8.82) 3.81 (1.51, 9.58)
Cox proportional hazards
Reintervention .0001 .0001 3.46 (1.85, 6.47) 3.55 (1.85, 6.83)
Primary patency .0001 .0001 10.01 (3.20, 31.30) 10.51 (3.22, 34.29)
CI, Confidence interval.
*For all comparisons, treatment variable was EVAR vs OR.
†Ratios for logistic regression results are odds ratios; ratios for Cox proportional hazards results are hazard ratios.
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conversion to open repair for AAA rupture 5 months after
insertion of a bifurcated AneuRx stent-graft. The patient
underwent an aortobiliac polyester graft placement done
retroperitoneally. The AAA inspection and culture did not
reveal infection. He was discharged 30 days later. The
second patient underwent an angiogram with successful
endovascular treatment of a type II and III endoleak.
Primary patency, primary-assisted patency, and second-
ary patency were all significantly different for the two
groups (P  .0001, P  .02, and P  .02, respectively).
Primary patency rates at 1 year for the EVAR and OR group
were 83% (95% CI: 73% to 95%) and 98% (95% CI: 96% to
100%), respectively (Fig 2, online only). Primary-assisted
patency rates at 1 year for the EVAR and OR group were
94% (95% CI: 86% to 99%) and 99% (95% CI: 96% to
100%), respectively (Fig 3, online only). Secondary patency
rates at 1 year for the EVAR and OR group were 96% (95%
CI: 89% to 100%) and 99% (95% CI: 98% to 100%),
respectively (Fig 4, online only).
Success rates at 1 year, defined as freedom from AAA-
related death, AAA rupture, or conversion, were, for the
EVAR and OR group respectively, 97% (95% CI: 90% to
100%) and 98% (CI: 96% to 100%; P  .68; Fig 5, online
only).
After adjusting for the effect of age, gender, and high-
risk status, the associations between the surgical repair type
(EVAR vs OR) and both reintervention rates and primary
patency rates remained significant (Table IX). Multivariable
analyses were not used for the other survival endpoints
because of small numbers of events. When looking at the
association between high-risk status and 30-day complica-
tion rates within each treatment group, we found no sig-
nificant association except between high-risk status and
graft-related complications in the OR group (10.8% of
high-risk patients had graft complications compared with
2.7% of normal risk patients, P  .04). Similar association
between high-risk status and cardiac or pulmonary compli-
cations rate after OR nearly reached significance (P  .09
for cardiac complications, P  .05 for pulmonary compli-
cations; see Fig 6).
DISCUSSION
This cohort study compared 30-day mortality and
complication rates and results of endovascular and open
elective AAA repair at 1 year after interventions. Both
groups of patients were treated at the same institution
during the same period by the same surgeons. EVAR was
performed in the operating room by a team of a vascular
surgeon and an interventional radiologist. Patients in the
endovascular group were older and at higher risk of com-
plications compared with the open repair group. Despite
these differences, 30-day cardiac and pulmonary complica-
tion rates, as well as the severity of these complications,
were lower in the endovascular group. EVAR patients had
a 21% reduction in the median operative time, a 50%
reduction in intraoperative blood loss and in the number of
patients receiving blood products, a 50% decrease in me-
dian ICU, and a 63% decrease in median hospital stay.
Median time to bowel function recovery decreased from 4
days to 1 day. Similar benefits of EVAR were reported by
other investigators as well.1,2,5
However, graft-related complications and reinterven-
tion rate were higher, and patency rates were lower, after
endovascular repair compared with open repair. These dif-
ferences remained statistically significant after accounting
for age, gender, and high-risk status in a multivariate
model.
There was no significant difference in 30-day mortality
between OR and EVAR patients. Although mortality of
1.2% after OR in this study was lower than the 8.2% rate
reported in two prospective population-based studies on
elective AAA surgery,6,7 it is similar to the national average
mortality rate of 3.8% after OR of abdominal aortic aneu-
rysm.8 Because many EVAR patients had more risk factors
than those who underwent OR, it is safe to say that EVAR
is not associated with a higher 30-day mortality than that
experienced by OR patients.
The rate of cardiac complications was more frequent
after OR than after EVAR: the 30-day cardiac morbidity
rate was 22%. This rate is similar to the 21% rate reported by
Makaroun2 in the control arm of the Ancure phase II
multicenter trials or the 19% and 27% rates reported by
Sicard et al9 in their randomized trial comparing the retro-
peritoneal and transperitoneal OR. Although lower cardiac
morbidity has been reported for open repair in previous
studies,10 differences in cardiac morbidity definition, such
as exclusion of “minor” cardiac complications, and in se-
lection of patients may explain these findings. In our study,
cardiac morbidity rate in the EVAR group was 11%, a
relative reduction of 50% compared with the OR group. A
decrease in cardiac morbidity rate was also observed with
endovascular repair in the Ancure phase II trial. The less
invasive approach, lack of laparotomy, absence of aortic
cross-clamping, and reduction in fluid requirements are the
most important elements to explain the lower cardiac com-
plication rate associated with EVAR.
The pulmonary morbidity rate was 3% in the endovas-
cular group, compared with 16% in the open repair group,
Fig 1. Cumulative freedom from reintervention after abdominal
aortic aneurysm repair in the OR and EVAR group. The dotted
line represents SEM of 10%.
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a relative reduction of 80% compared with open repair.
There was no significant difference in the renal morbidity
rates. The Society for Vascular Surgery complication sever-
ity codes for the cardiac, pulmonary, renal, and wound
complications groups were all higher in the OR group. For
example, there were six cardiac arrests in the OR group and
none in the EVAR group, and two patients needed perma-
nent dialysis after OR compared with none among those
who had had EVAR.
The 30-day graft-related complications rate was signif-
icantly higher in the EVAR than the OR group. The same
difference was reported in the Ancure phase II trial, in
which 3% of the EVAR patients presented with early graft
occlusion.2 Graft limb thrombosis occurred in 3% of EVAR
patients in the AneuRx phase II trial.1 A 4.3% early graft-
related complication rate after 1554 EVAR procedures was
reported in the Eurostar registry; this record also noted an
association between experience of the operating team and
the rate of complications: morbidity decreased significantly
after the performance of 30 procedures.11
Despite the shorter hospital stay length in the EVAR
group, readmission within the first 30 days was not signif-
icantly different between the two groups. Reinterventions
were more frequent after endovascular repair, with a 35%
reintervention rate in the endovascular group at 1 year.
Most of these were due to complications such as graft
Fig 6. Association between high-risk status and 30-day complication rates for each treatment group. A, Rates for
cardiac complications. B, Rates for pulmonary complications. C, Rates for graft-related complications.
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occlusion or severe stenosis, renal artery occlusion, type I
endoleak, and, in one patient, AAA rupture. The freedom-
from-reintervention rate at 1 year that was reported in the
Ancure phase II trial update was 85%, but this rate did not
include the 25 patients requiring immediate conversion.12
The freedom-from-reintervention rate at 1 year that was
reported in the Eurostar registry was 89%, but this analysis
again excluded 35 patients who had conversion within the
first month after the endograft placement.13 The freedom-
from-secondary-procedures rate in the AneuRx trial was
94%.14 The important difference between this rate and the
rate observed in our study could be explained by variation
in this endpoint definition. Although all therapeutic proce-
dures done for a complication after AAA treatment were
considered reintervention in our study, interventions re-
lated to wound complications were not considered second-
ary procedures in the AneuRx trial. Patient selection may
also explain some of the differences. Eighteen percent of
the patients treated with EVAR in the present study had an
angulated or short (10 mm) proximal aortic neck.
The increase in reintervention after EVAR compared
with OR has been reported by several investigators.15,16
However, as knowledge about endografts is evolving, bet-
ter patient selection and improvement in intraoperative
management will likely reduce the reintervention rate. Of
interest, three of four reinterventions in our study were
performed using an endovascular approach, a proportion
similar to the 80% reported by Makaroun et al.15 Also,
preoperative internal iliac artery embolizations were not
taken into account for calculation of EVAR intervention
time..
Graft patency rates at 1 year were significantly reduced
in the EVAR group compared with in the OR group.
However, among the 12 patients with loss of primary
patency within the first year in the present study, 3 of the
instances were related to endoleak treatment with stenting
or percutaneous transluminal angioplasty over the device.
The primary assisted patency rate of 94% at 1 year compares
well with the 97% rate at 6 months that was reported in the
AneuRx phase II trial. The primary assisted patency in the
phase II Ancure trial was 93.7% at a mean follow-up period
of 31 months.17 Of interest, the proportion of patients with
aortoiliac occlusive disease in the present study was similar
in both groups.
Results from randomized prospective trials comparing
the two techniques of AAA repair are not yet available.
Comparison of conventional open AAA repair and endo-
vascular repair is subject to several flaws, such as patient
selection bias, learning curve bias in favor of open repair,
and variation in the reporting standards. Unfortunately,
this study also carries its limitations. The differences in
patient selection between the two treatment groups should
call for careful interpretation of findings. In an attempt to
take into account these differences, we used a multivariate
model accounting for the effect of age, gender, and high-
risk status; it showed that the difference in cardiac, pulmo-
nary, and graft-related complications between surgery
groups remained significant. A learning curve bias in favor
of open repair could also be present when comparing open
repair with the initial patients undergoing the EVAR pro-
cedure. Also, in theory, the excellent results in the open-
repair group might have been aided by offering EVAR to
several high-risk patients. Procedure time, blood loss, and
intensive care unit time were significantly lower in phase II
of the AneuRx trial compared with in phase I, illustrating
this learning curve bias for the EVAR patients. However,
our endovascular experience dates back to nearly 3 years
before the inclusion date in the present study. Also, the
retrospective design of the study may have resulted in
underestimation of the incidence of some of the complica-
tions, such as buttock claudication. Finally, the short fol-
low-up for several of the patients in the EVAR group will
likely improve the early results in that group.
We conclude that both elective open and endovascular
repair can be performed with low mortality, but cardiac and
pulmonary complications are less frequent and ICU and
postoperative stay are shorter after endovascular repair,
especially for high-risk patients. Cardiac, pulmonary, and
renal complications were less severe in the endovascular
group compared with the open repair group. The tradeoff
of endovascular repair is a higher rate of graft-related com-
plications, with more reinterventions and a lower graft
patency rate at 1 year. However, these reinterventions are
mostly performed through an endovascular approach.
Longer follow-up and late clinical outcomes are essential,
but these early results should also be considered before
endovascular repair is offered to patients who are fit for
open AAA repair. The gray zone remains the patient pop-
ulation with limited life expectancy because of advanced
age (80 years old) but that still represents a relatively
good risk for open repair because of lack of associated
comorbidities. In this group, patient preference for endo-
vascular repair, with the aim to return to early activity and
potentially better quality of life, should be strongly consid-
ered.
The authors thank Mrs Marcia Simonson for her assis-
tance with manuscript preparation.
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